Education
About Us
Working with TipRanks
Follow Us
CanBas Co., Ltd. (JP:4575)
:4575
4575 Stock Chart & Stats
¥780.00
-¥23.00(-2.48%)
At close: 4:00 PM EST
¥780.00
-¥23.00(-2.48%)
Day’s Range― - ―
52-Week Range¥739.00 - ¥1,558.00
Previous CloseN/A
Volume347.00K
Average Volume (3M)268.48K
Market Cap
¥15.89B
Enterprise Value¥18.97B
Total Cash (Recent Filing)¥2.83B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Feb 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.69
Shares Outstanding19,713,655
10 Day Avg. Volume208,910
30 Day Avg. Volume268,476
Financial Highlights & Ratios
PEG Ratio1.96
Price to Book (P/B)7.69
Price to Sales (P/S)0.00
P/FCF Ratio-29.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
4575 FAQ
What was CanBas Co., Ltd.’s price range in the past 12 months?
CanBas Co., Ltd. lowest stock price was ¥739.00 and its highest was ¥1558.00 in the past 12 months.
What is CanBas Co., Ltd.’s market cap?
CanBas Co., Ltd.’s market cap is ¥15.89B.
When is CanBas Co., Ltd.’s upcoming earnings report date?
CanBas Co., Ltd.’s upcoming earnings report date is Feb 06, 2026 which is in 43 days.
How were CanBas Co., Ltd.’s earnings last quarter?
CanBas Co., Ltd. released its earnings results on Nov 11, 2025. The company reported -¥17.69 earnings per share for the quarter, missing the consensus estimate of N/A by -¥17.69.
Is CanBas Co., Ltd. overvalued?
According to Wall Street analysts CanBas Co., Ltd.’s price is currently Overvalued.
Does CanBas Co., Ltd. pay dividends?
CanBas Co., Ltd. does not currently pay dividends.
What is CanBas Co., Ltd.’s EPS estimate?
CanBas Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CanBas Co., Ltd. have?
CanBas Co., Ltd. has 19,713,655 shares outstanding.
What happened to CanBas Co., Ltd.’s price movement after its last earnings report?
CanBas Co., Ltd. reported an EPS of -¥17.69 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.861%.
Which hedge fund is a major shareholder of CanBas Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4575
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CanBas Co., Ltd.
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
Renascience Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―